Clinical Trial Update: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Olaparib plus Durvalumab in EGFR-mutated non-small cell lung cancer that transformed to small cell lung cancer and other neuroendocri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine | Phase 2 | Status: TERMINATED | Results posted: 2025-01-27